Multi-omics Dissection of MAPK-driven Senescence Unveils Therapeutic Vulnerabilities in KIAA1549::BRAF-fusion Pediatric Low-Grade Glioma Models
RNA-seq (gene expression) · human · 15 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 15 samples: 5 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Multi-omics dissection of MAPK-driven senescence unveils therapeutic vulnerabilities in KIAA1549::BRAF-fusion pediatric low-grade glioma modelsSignal transduction and targeted therapy · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE287599_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1213793 and SRA study SRP558748. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 15 samples.
How we read this: 5 replicated groups read from 15 sample titles; they account for 15 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8748755 DKFZ-BT66-OFF_Ctrl_Rep1 DKFZ-BT66-OFF_Ctrl
- GSM8748756 DKFZ-BT66-OFF_Ctrl_Rep2 DKFZ-BT66-OFF_Ctrl
- GSM8748757 DKFZ-BT66-OFF_Ctrl_Rep3 DKFZ-BT66-OFF_Ctrl
- GSM8748758 DKFZ-BT66-OFF_100nM trametinib 15min_Rep1 DKFZ-BT66-OFF_100nM tra…
- GSM8748759 DKFZ-BT66-OFF_100nM trametinib 15min_Rep2 DKFZ-BT66-OFF_100nM tra…
- GSM8748760 DKFZ-BT66-OFF_100nM trametinib 15min_Rep3 DKFZ-BT66-OFF_100nM tra…
- GSM8748761 DKFZ-BT66-OFF_100nM trametinib 1h_Rep1 DKFZ-BT66-OFF_100nM tra…
- GSM8748762 DKFZ-BT66-OFF_100nM trametinib 1h_Rep2 DKFZ-BT66-OFF_100nM tra…
- GSM8748763 DKFZ-BT66-OFF_100nM trametinib 1h_Rep3 DKFZ-BT66-OFF_100nM tra…
- GSM8748764 DKFZ-BT66-OFF_100nM trametinib 6h_Rep1 DKFZ-BT66-OFF_100nM tra…
- GSM8748765 DKFZ-BT66-OFF_100nM trametinib 6h_Rep2 DKFZ-BT66-OFF_100nM tra…
- GSM8748766 DKFZ-BT66-OFF_100nM trametinib 6h_Rep3 DKFZ-BT66-OFF_100nM tra…
- GSM8748767 DKFZ-BT66-OFF_100nM trametinib 24h_Rep1 DKFZ-BT66-OFF_100nM tra…
- GSM8748768 DKFZ-BT66-OFF_100nM trametinib 24h_Rep2 DKFZ-BT66-OFF_100nM tra…
- GSM8748769 DKFZ-BT66-OFF_100nM trametinib 24h_Rep3 DKFZ-BT66-OFF_100nM tra…
- GSE275870 Expression profiling of primary and metastatic oral squamous cell carcinoma identifies progression-associated transcriptome changes and therapeutic vulnerabilities 108 samples shares vulnerabilities, therapeutic
- GSE294016 A macrophage-predominant, immunosuppressive immune microenvironment and subtype-specific therapeutic vulnerabilities in advanced salivary gland cancer [bulk RNA-seq] 95 samples shares vulnerabilities, therapeutic
- GSE273036 Multi-Omics Analysis and Molecular Subtypes Provide Potential Therapeutic Implications in Fumarate Hydratase-deficient Renal Cell Carcinoma 93 samples shares multi-omics, therapeutic
- GSE319124 Next-GenerationPediatric Cancer Models: Patient-Matched Orthotopic Xenografts, 3D Organoids, 2D Cultures, and Cell Lines for Identification of Therapeutic Vulnerabilities in Pediatric Solid Tumors [scRNAseq] 59 samples shares vulnerabilities, therapeutic
- GSE294017 A macrophage-predominant, immunosuppressive immune microenvironment and subtype-specific therapeutic vulnerabilities in advanced salivary gland cancer [Single nuclei RNAseq] 16 samples shares vulnerabilities, therapeutic
- GSE269942 YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities 12 samples shares vulnerabilities, therapeutic
- GSE274284 Multi-omics dissection of human RAG deficiency reveals distinctive patterns of immune dysregulation but a common inflammatory signature 63 samples shares multi-omics, dissection
- GSE285857 Mutant KRAS-Driven Selective mRNA Translation Reveals Mechanisms and Therapeutic Vulnerabilities in Cancer 48 samples shares vulnerabilities, therapeutic
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.